Pharmaeconomica utilizes a proprietary AI-driven platform to optimize small-molecule drug discovery, significantly reducing the need for extensive experimental screening and accelerating the identification of lead compounds. Focused on complex diseases like Alzheimer's, the platform enhances efficiency and cost-effectiveness in developing effective therapies, ultimately improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional small-molecule drug discovery is a resource-intensive process, often requiring extensive experimental screening to identify viable lead compounds. This approach can be particularly challenging for complex diseases, leading to prolonged development timelines and increased costs.
Solution
Pharmaeconomica offers an AI-driven drug discovery platform, PREDIT, that leverages computational chemistry and machine learning to accelerate the identification and optimization of small-molecule drug candidates. PREDIT constructs protein structures without experimental data and employs proprietary algorithms to distinguish active compounds, predict molecular interactions, and optimize molecule designs. The platform integrates a database of approximately 4 billion compounds, including peptides, and uses virtual screening, homology modeling, and molecular dynamics simulations to identify promising chemical scaffolds with high affinity and selectivity for specific targets. By reducing the need for extensive experimental screening, Pharmaeconomica aims to enhance the efficiency and cost-effectiveness of drug development.
Target Audience
Pharmaeconomica primarily targets pharmaceutical companies and research institutions involved in small-molecule drug discovery, particularly those focused on complex diseases such as neurological disorders, viral infections, and obesity.
Features
- AI-driven platform (PREDIT) for targeted drug discovery
- Advanced predictive modeling using deep learning and graph neural networks
- Generative design algorithms for creating novel compounds
- Reinforcement learning for optimized molecular modification
- Few-shot learning, transfer learning, and synthetic data generation for low-data optimization
- Active learning, Bayesian models, custom ensemble methods, and hybrid models for sparse data handling
- Proprietary frameworks for explainable AI
- Virtual screening pipeline integrating diverse molecular docking software
- Homology modeling for constructing 3D structures of target proteins
- Molecular dynamics simulations to evaluate stability of top hits